Gastroretentive oral dosage unit containing a local anesthetic

A gastroretentive oral dosage unit with a local anesthetic core provides prolonged gastric retention and controlled release, effectively treating malnutrition and excessive satiety by suppressing gastric muscle contractions.

JP2024543262APending Publication Date: 2024-11-20OREXA BV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2024531272
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-25
Filing Date
2022-10-26
Publication Date
2024-11-20

AI Technical Summary

Technical Problem

Existing oral dosage forms fail to effectively address malnutrition and premature or excessive satiety, particularly in older adults and postoperative patients, due to inadequate gastric retention and rapid drug release.

Method used

A gastroretentive oral dosage unit containing a core comprising a local anesthetic, a blowing agent, a hydrophilic polymer, and excipients, which forms a buoyant matrix in gastric fluid, allowing gradual drug release and prolonged gastric residence.

Benefits of technology

The dosage unit effectively suppresses satiety by prolonged local anesthetic release, addressing malnutrition and reducing the risk of postoperative intestinal obstruction through extended gastric retention and controlled drug delivery.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024543262000001
    Figure 2024543262000001
  • Figure 2024543262000002
    Figure 2024543262000002
  • Figure 2024543262000003
    Figure 2024543262000003
Patent Text Reader

Abstract

The present invention provides a gastric retentive oral dosage unit having a weight of 150-1,000 mg, said dosage unit comprising 70-100% by weight of a core unit and 0-30% by weight of a coating, the core unit comprising: (a) 15-50% by weight of a local anesthetic; (b) 2-20% by weight of an effervescent agent; (c) 8-30% by weight of a hydrophilic water soluble polymer; and (d) 5-75% by weight of an excipient. The dosage unit of the present invention is particularly suitable for treating or preventing malnutrition or for treating or preventing early or excessive satiety in subjects with sufficient nutritional access.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a gastroretentive oral dosage unit containing a local anesthetic and a method for preparing such a dosage unit. The present invention further relates to the use of this dosage unit in the treatment or prevention of malnutrition in subjects with sufficient nutritional access or in the treatment of early or excessive satiety. [Background technology]

[0002] "Age-related anorexia" refers to the decrease in appetite and energy intake observed in some older people. Satiety (the process that results in the cessation of eating, which may be accompanied by a feeling of satisfaction) and satiety (the feeling of fullness that persists after a meal, which may inhibit further energy intake until hunger returns) are important factors in the control of appetite and energy intake, and there is evidence that some aspects of satiety and satiety are altered in older people.

[0003] Cachexia is a complex syndrome associated with underlying diseases that causes progressive muscle weakness that is not adequately reversed by nutritional supplementation. A variety of diseases can cause cachexia, most commonly cancer, congestive heart failure, chronic obstructive pulmonary disease, chronic kidney disease, and AIDS. Early (too early) satiety has been identified as a contributing factor. In contrast to weight loss due to inadequate caloric intake, cachexia primarily causes muscle weakness instead of fat loss.

[0004] Next to the chronic symptoms of early or excessive satiety, there are also acute symptoms. After abdominal surgery, many patients have problems starting meals. Loss of appetite or excessive satiety can lead to postoperative ileus. Postoperative ileus is characterized by intolerance to solid foods, delayed passage of intestinal gas and formed stool, pain and abdominal distension, nausea, vomiting, and retention of gas or water in the intestines. Postoperative ileus often leads to prolonged hospital stays.

[0005] Local anesthetics such as lidocaine, in contrast to general anesthetics, relieve pain in a specific location of the body without loss of consciousness. Local anesthetics belong to one of two classes: aminoamide and aminoester local anesthetics. Synthetic local anesthetics are structurally related to cocaine. They differ from cocaine primarily in that they have a very low abuse potential and do not cause hypertension or (with few exceptions) vasoconstriction.

[0006] Lidocaine is a local anesthetic of the aminoamide type that is primarily administered by either injection and / or topical / transdermal routes. Lidocaine's efficacy profile as a local anesthetic is characterized by a rapid onset of action and an intermediate duration of effectiveness.

[0007] Lidocaine is one of the most commonly used local anesthetics in dentistry. For surface anesthesia, several preparations may be used, such as before intubation of an endoscope. Buffering the pH of lidocaine reduces the pain of localized numbing. Lidocaine drops may be used in the eyes for brief ophthalmic surgery.

[0008] Trachisan® is an over-the-counter lidocaine lozenge that relieves sore throat.

[0009] Quadeib et al. (The Oral Administration of Lidocaine HCl Biodegradable Microspheres: Formulation and Optimization, Int J Nanomedicine. 2020; 15: 857-869.) describes an oral lidocaine formulation that improves the solubility of lidocaine and enhances its release in vitro. Various ratios of alginate and chitosan were used to create different types of microspheres. According to the authors, the microspheres can be used as a novel oral delivery system for lidocaine and exhibit significantly lower cardiotoxicity than lidocaine alone.

[0010] WO 2013 / 171252 describes a method for promoting food intake and food retention in a mammal by applying a sufficient dose of a local anesthetic to the lumen of the pharynx-esophagus-gastro-duodenal tract before, during or after a meal. Lidocaine is mentioned as an example of a local anesthetic.

[0011] In the specification of U.S. Patent Application Publication No. 2011 / 0287096, (a) a gastroretentive component comprising a basic amine drug, an acidifying agent, a carbon compound, a hydrophilic insoluble polymer, and a water-insoluble fluid osmotic agent; and (b) a non-gastroretentive component comprising a basic amine drug, an acidifying agent, and a sustained release polymer; An oral dosage form comprising:

[0012] US Patent Publication No. 2020 / 0316150 describes a sustained release gastroretentive swellable oral formulation comprising a bergenin-rich hydroalcoholic extract or fraction of Bergenia ciliata; a gastroretentive swellable polymer selected from the group consisting of hydroxypropyl methylcellulose (HPMC) K15M, HPMC K30M, HPMC K100M, xanthan gum, chitosan, ethylcellulose with a viscosity in the range of 10-100 cps, sodium alginate, and combinations thereof; and, optionally, an excipient selected from the group consisting of a carrier, an adjuvant, and a binder. Summary of the Invention [Means for solving the problem]

[0013] The inventors have developed a dosage unit that is particularly suitable for treating or preventing malnutrition in subjects with sufficient nutritional access, or for treating or preventing early or excessive satiety. The dosage unit according to the invention can be taken orally and then slowly releases the local anesthetic in the stomach over an extended period of time.

[0014] The gastric retentive oral dosage unit of the present invention has a weight of 150-1,000 mg and comprises 70-100% by weight of a core unit and 0-30% by weight of a coating, the core unit being (a) 15-50% by weight of a local anesthetic; (b) 2 to 20 weight percent of a blowing agent; (c) 8 to 30 wt. % of a hydrophilic polymer; (d) 5 to 75% by weight of an excipient Includes.

[0015] Although the inventors do not wish to be bound by theory, it is believed that when the dosage unit of the present invention comes into contact with gastric fluids, the effervescent agent begins to release gas bubbles while the hydrophilic polymer begins to form a wet matrix that traps these gas bubbles. The buoyancy resulting from this cooperation causes the dosage unit to float, thereby increasing the residence time of the dosage unit in the stomach. The wet polymer matrix prevents or at least delays disintegration of the dosage unit, so that the local anesthetic is released gradually. The gradual and prolonged release of the local anesthetic is important to achieve a sustained effect, especially if the local anesthetic is inactivated when in contact with gastric fluids.

[0016] The gastroretentive oral dosage units of the present invention offer the advantage of being easy to manufacture, for example, since they do not include an elastic membrane. Furthermore, the release characteristics of the dosage units can be effectively and easily manipulated by adjusting the concentration levels of the components of the core unit.

[0017] The present invention also relates to the use of the dosage unit described above in the treatment or prevention of malnutrition or early or excessive satiety in subjects with sufficient nutritional access, comprising oral administration of the dosage unit. After oral administration of the dosage unit, the local anesthetic is gradually released in the stomach for an extended period of time, causing suppression of early satiety. This suppression of satiety is believed to be caused by relaxation of muscle fibers in the stomach wall tissue induced by the local anesthetic.

[0018] 1. A method for preparing a dosage unit of the present invention, comprising: preparing a tableting mixture by homogeneously mixing components (a), (b), (c) and (d); and Tableting Compressing the mixture into tablets A method is also provided that includes: DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0019] Accordingly, a first aspect of the present invention is a gastric retentive oral dosage unit having a weight of 150-1,000 mg, said dosage unit comprising 70-100% by weight of a core unit and 0-30% by weight of a coating, wherein the core unit is (a) 15-50% by weight of a local anesthetic; (b) 2 to 20 weight percent of a blowing agent; (c) 8 to 30 wt. % of a hydrophilic polymer; (d) 5 to 75% by weight of an excipient The present invention relates to a gastroretentive oral dosage unit comprising:

[0020] The term "local anesthetic" as used herein refers to an agent that relieves pain in a specific location of the body without loss of consciousness. These local anesthetics can be present in the dosage unit in any pharma- ceutically acceptable form, including pharma- ceutically acceptable salts.

[0021] The term "topical anesthetic" as used herein refers to a local anesthetic that, when applied topically, relieves pain in tissue.

[0022] As used herein, the term "lidocaine" includes lidocaine as well as its pharma- ceutically acceptable salts (such as lidocaine.HCl).

[0023] The term "hydrophilic polymer" as used herein refers to a polymer that is water-swellable and / or water-soluble.

[0024] The dosage unit of the present invention is preferably provided in the form of a tablet, more preferably a compressed tablet. The tablet preferably has a tablet strength of at least 40N, more preferably between 80 and 140N.

[0025] The dosage units of the present invention offer the advantage that they can be prepared in a very simple manner by homogeneously mixing components (a)-(d), followed by tabletting and optionally applying a protective coating. Thus, in a preferred embodiment, components (a)-(d) are homogeneously mixed.

[0026] According to a preferred embodiment, the local anesthetic used in accordance with the present invention is a topical anesthetic, which offers the advantage of being highly effective at low dosages.

[0027] The local anesthetic is preferably selected from lidocaine, benzocaine, bupivacaine, oxethazaine, prilocaine, butanilicaine, carticaine, cinchocaine, clibucaine, etidocaine, mepivacaine, ropivacaine, tricaine, trimecaine, vadocaine, articaine, levobupivacaine, amylocaine, cocaine, propanocaine, chlormecaine, cyclomethycaine, proxymethacaine, amethocaine, butacaine, butoxycaine, butyl aminobenzoate, chloroprocaine, dimethocaine, oxybuprocaine, piperocaine, parethoxycaine, procaine, propoxycaine, tricaine, and combinations thereof. More preferably, the local anesthetic is selected from lidocaine, benzocaine, bupivacaine, oxethazaine, prilocaine, and combinations thereof. Most preferably, the local anesthetic is lidocaine.

[0028] The local anesthetics used in accordance with the present invention are preferably aminoamide type local anesthetics.

[0029] The dosage unit of the present invention preferably contains 30 to 400 mg, more preferably 40 to 300 mg, and most preferably 50 to 200 mg of local anesthetic.

[0030] The amount of lidocaine contained in a dosage unit is preferably in the range of 30 to 400 mg, more preferably in the range of 40 to 300 mg, and most preferably in the range of 50 to 200 mg.

[0031] The core unit of the dosage unit of the present invention preferably contains 20 to 45% by weight, more preferably 30 to 40% by weight, of a local anesthetic.

[0032] The core unit of the dosage unit preferably contains 20-45% by weight of lidocaine, more preferably 30-40% by weight.

[0033] The lidocaine may be present in the core unit in any pharma- ceutically acceptable form. Preferably, the lidocaine used is lidocaine hydrochloride.

[0034] The effervescent agent in the core unit preferably releases carbon dioxide when contacted with gastric fluids.

[0035] According to a particularly preferred embodiment, the effervescent agent is selected from bicarbonates, carbonates, and combinations thereof. More preferably, the effervescent agent is selected from ammonium bicarbonate, calcium bicarbonate, lithium bicarbonate, magnesium bicarbonate, potassium bicarbonate, sodium bicarbonate, arginine carbonate, ammonium carbonate, calcium carbonate, lysine carbonate, magnesium potassium carbonate, sodium carbonate, sodium glycine carbonate, sodium sesquicarbonate, zinc carbonate, and combinations thereof. Even more preferably, the effervescent agent is selected from sodium bicarbonate, potassium bicarbonate, sodium carbonate, potassium carbonate, and combinations thereof. Most preferably, the effervescent agent is sodium bicarbonate.

[0036] The core unit of the dosage unit preferably contains 3 to 18 wt. %, more preferably 4 to 16 wt. %, most preferably 4 to 12 wt. % of the foaming agent.

[0037] The hydrophilic polymer present in the core unit is preferably selected from hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, ethylcellulose, methylcellulose, carboxymethylcellulose, carboxymethylstarch, polyethylene oxide, carbomer, polyvinyl alcohol, polyvinylpyrrolidone, vinylpyrrolidone-vinyl acetate copolymer, methacrylic acid copolymer, polyacrylic acid, carrageenan, natural gum, guar gum, tragacanth, acacia gum, locust bean gum, xanthan gum, and combinations thereof. More preferably, the hydrophilic polymer is selected from hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, ethylcellulose, methylcellulose, carboxymethylcellulose, and combinations thereof. Most preferably, the hydrophilic polymer is hydroxypropylmethylcellulose (HPMC).

[0038] The core unit preferably contains 10 to 25% by weight, more preferably 12 to 20% by weight, of a hydrophilic polymer.

[0039] The excipient is preferably contained in the core unit at a concentration of 10-60% by weight, more preferably 25-50% by weight, and most preferably 32-45% by weight.

[0040] According to a particularly preferred embodiment, the combination of components (a)-(d) comprises at least 75% by weight of the core unit, more preferably at least 85% by weight of the core unit, and most preferably at least 90% by weight of the core unit.

[0041] The excipients included in the core unit preferably comprise a filler selected from lactose, microcrystalline cellulose, mannitol, starch and combinations thereof. More preferably, the filler is selected from lactose, microcrystalline cellulose and combinations thereof. Most preferably, the filler comprises microcrystalline cellulose.

[0042] The core unit preferably contains 0-40% by weight lactose and 0-45% by weight microcrystalline cellulose. More preferably, the core unit contains 1-20% by weight lactose and 20-40% by weight microcrystalline cellulose. Most preferably, the core unit contains 2-10% by weight lactose and 26-38% by weight microcrystalline cellulose.

[0043] The core unit preferably contains 20 to 70% by weight of filler, more preferably 25 to 50% by weight of filler, and most preferably 28 to 45% by weight of filler.

[0044] According to a particularly preferred embodiment, the core unit contains a disintegrant selected from croscarmellose, sodium starch glycolate, crospovidone, and combinations thereof. More preferably, the disintegrant is selected from croscarmellose, sodium starch glycolate, and combinations thereof.

[0045] The core unit preferably contains 0.5 to 15% by weight of disintegrant, more preferably 0.7 to 10% by weight of disintegrant, even more preferably 0.8 to 6% by weight of disintegrant, even more preferably 1 to 5% by weight of disintegrant, and most preferably 1.4 to 4% by weight of disintegrant.

[0046] According to a further preferred embodiment, the core unit contains an antacid. Examples of antacids that may be used include calcium gluconate, calcium citrate, sodium gluconate, sodium citrate, sodium hydroxide, potassium gluconate, potassium citrate, potassium hydroxide, magnesium carbonate, magnesium gluconate, magnesium citrate, magnesium hydroxide, magnesium oxide, aluminum gluconate, aluminum citrate, aluminum hydroxide and combinations thereof.

[0047] The core unit preferably contains 5-30% by weight of antacid, more preferably 8-25% by weight of antacid.

[0048] In a preferred embodiment of the dosage unit, the core unit comprises a water-soluble divalent metal salt, more particularly Ca 2+ and / or Mg 2+ The water-soluble divalent metal salt may be a water-soluble antacid. As used herein, "water-soluble" refers to a salt having a solubility of at least 50 mg / L in distilled water acidified with HCl to a pH of 1.2. When a dosage unit containing an alginate and a water-soluble divalent metal salt comes into contact with gastric fluid, the divalent metal salt dissolves, thereby releasing the divalent metal, which subsequently crosslinks the alginate under the formation of a gel network.

[0049] The water-soluble divalent metal salt is preferably a water-soluble calcium salt. Examples of water-soluble calcium salts that can be suitably used in the core unit include calcium carbonate, calcium lactate, calcium chloride, calcium phosphate, and combinations thereof. Most preferably, the water-soluble divalent metal salt is calcium carbonate.

[0050] The alginate used in the core unit is preferably selected from alginic acid, sodium alginate, potassium alginate and combinations thereof. Most preferably, the alginate is sodium alginate.

[0051] The alginate is preferably contained in the core unit at a concentration of 0.01 to 1% by weight, more preferably 0.03 to 0.5% by weight.

[0052] The water-soluble divalent metal salt is preferably contained in the core unit at a concentration of 1 to 100 mmol / L, more preferably 2 to 20 mmol / L.

[0053] According to a particularly preferred embodiment, the core unit comprises a combination of an antacid, an alginate and a water-soluble divalent metal salt.

[0054] According to yet another embodiment, the core unit contains a lubricant.Examples of lubricants that can be used include sodium stearate, magnesium stearate, zinc stearate, aluminum stearate, stearic acid, palmitic acid, calcium hydroxide, talc, corn starch, sodium stearyl fumarate, leucine, polyethylene glycol, glyceryl behenate, colloidal silicon dioxide, hydrogenated vegetable oils, mineral oils, waxes, and combinations thereof.More preferably, the lubricant is selected from sodium stearate, magnesium stearate, zinc stearate, aluminum stearate, and combinations thereof.

[0055] The core unit preferably contains 0.2 to 3% by weight of lubricant, more preferably 0.3 to 2% by weight of lubricant, and most preferably 0.5 to 1.5% by weight of lubricant.

[0056] To prevent release of the local anesthetic in the mouth, the core unit is preferably surrounded by a saliva-resistant coating that minimizes undesired release of the local anesthetic in the mouth or throat.

[0057] The saliva-resistant coating preferably comprises at least 50% by weight, more preferably at least 80% by weight, of a cationic copolymer based on dimethylaminoethyl methacrylate, more preferably a copolymer based on dimethylaminoethyl methacrylate, butyl methacrylate and methyl methacrylate (e.g. Eudragit® E).

[0058] The dosage unit preferably comprises 3-30% by weight, more preferably 4-15% by weight, of the saliva-resistant coating.

[0059] The performance of the dosage unit of the present invention can be determined in a dissolution test using artificial gastric fluid. The test is performed using a USP2 apparatus and 900 mL of artificial gastric fluid (pH 1.2). A detailed description of the test can be found in The United States Pharmacopeial Convention. General Chapter: 711 Dissolution: Apparatus 2. The United States Pharmacopeia and The National Formulary. USP 34-NF 29. Rockville, MD: The United States Pharmacopeial Convention, 2011. Preferably, in this dissolution test, the dosage unit of the present invention released 15-60% of the local anesthetic after 10 minutes and 60-100% of the local anesthetic after 60 minutes. More preferably, in this dissolution test, the dosage unit of the present invention released 20-50% of the local anesthetic after 10 minutes and 80-100% of the local anesthetic after 60 minutes.

[0060] Another aspect of the present invention relates to a dosage unit for use in the treatment or prevention of malnutrition or the treatment or prevention of early or excessive satiety in a subject with sufficient nutritional availability, said use comprising oral administration of a gastroretentive oral dosage unit as described hereinbefore.

[0061] The subject is preferably a human subject. More preferably, the subject is a human subject suffering from age-related anorexia, cachexia, malnutrition, post-operative ileus, anorexia nervosa or sarcopenia.

[0062] In a further preferred embodiment, the subject is a human patient undergoing surgery, in particular abdominal surgery. Oral administration of a gastroretentive dosage unit to this type of patient offers the advantage of reducing the risk of developing postoperative ileus.

[0063] Use of the dosage unit preferably involves at least one consecutive daily administration of the dosage unit.

[0064] According to a particularly preferred embodiment, the oral dosage unit is administered up to 30 minutes, more preferably up to 15 minutes, and most preferably up to 10 minutes before the start of intake of a meal.

[0065] Use of dosage units according to the present invention preferably involves oral administration of a dosage unit providing a dose of local anesthetic of between 30 and 400 mg, more preferably a dose of local anesthetic of between 50 and 300 mg.

[0066] Use preferably involves oral administration of a dosage unit providing a dose of 30-400 mg lidocaine, more preferably a dose of 50-300 mg lidocaine.

[0067] Yet another aspect of the present invention is a method for preparing a dosage unit as hereinbefore described, comprising the steps of: preparing a tableting mixture by homogeneously mixing components (a), (b), (c) and (d); and Tableting Compressing the mixture into tablets The present invention relates to a method comprising the steps of:

[0068] In a preferred embodiment of the process of the present invention, the tableting mixture is passed through a sieve having a mesh size of 200-1000 μm, more preferably having a mesh size of 300-800 μm, before the compression step.

[0069] The method of the present invention preferably comprises the further step of applying a saliva-resistant coating.

[0070] The saliva-resistant coating may be applied by dry powder coating or by coating with a liquid coating mixture comprising a solvent and a coating polymer. Preferably, the saliva-resistant coating is applied by applying a liquid coating mixture to the compressed tablets and allowing the solvent to evaporate.

[0071] The present invention is further illustrated by the following examples. EXAMPLES

[0072] Example 1 Oral dosage units according to the present invention were prepared according to the recipe shown in Table 1.

[0073] [Table 1]

[0074] The tablets were prepared as follows: Lidocaine and all excipients were sieved, weighed, and all (except magnesium stearate) were transferred to a mixing vessel. After 15 minutes of mixing, magnesium stearate was added and mixing was continued for an additional 5 minutes to obtain a tableting blend. The blend was compressed into round tablets.

[0075] Example 2 The tablet strength of the oral dosage units of Example 1 was determined using a Pharma Test™ hardness tester. Additionally, tests were performed to determine the floating time and disintegration time of the oral dosage units. The time until the tablets started to float was experimentally determined in a glass beaker containing 100 ml of simulated gastric fluid (pH 1.2). Disintegration testing was performed using an automated disintegration testing system (Parmatron DisiTest) containing discs.

[0076] The results of the study are shown in Table 2.

[0077] [Table 2]

[0078] Example 3 The dissolution profile of the tablets of Example 1 was determined using a USP2 apparatus filled with 900 mL of simulated gastric fluid (pH 1.2) and the results are shown in Figure 1.

[0079] Example 4 Lidocaine tablets were prepared according to the recipe shown in Table 3 using the same procedure as in Example 1.

[0080] [Table 3]

[0081] The tablets were then coated with a saliva-resistant coating at high temperature in a rotating drum by spraying the tablets with a coating solution (aqueous solution of Eudragit EPO). After drying, the weight of the tablets had increased by approximately 10% by weight.

[0082] The dissolution profiles of the coated tablets are shown in FIG.

[0083] Example 5 Within the gastrointestinal tract, local circuits play a role in the regulation of food intake and transport. Mechanical stretch of the stomach as a result of food intake activates stretch receptors (neurons), which in turn induce satiety signals. The pharmacology of stretch receptors can be analyzed in fundus strip preparations.

[0084] Fresh stomach tissue (0-1 h after euthanasia) was collected from routinely euthanized domestic pigs. The fundus region of the stomach was removed and washed with cold saline (0.9% NaCl) solution. The tissue was submerged in clean cold saline and transported to the laboratory (transport time 30 min).

[0085] The mucosa and submucosa were removed from the muscularis (muscle layer). The muscularis was cut along the longitudinal muscle fibers in strips of approximately 1 x 5 cm. The strips were incubated in saline solution at 37°C for 15 minutes.

[0086] The fundus strip was then placed vertically in a transparent container kept at 37° C. Tension was ensured by a 5 g weight at the bottom of the strip. The test solution was added into the container. Acetylcholine (10 -4Contraction of the fundus tissue was induced using exposure to 1000 μg / kg of ...

[0087] Table 4 shows the relative length of the fundus strips (percentage of baseline) following exposure to saline + acetylcholine (control) and saline + acetylcholine in combination with lidocaine (70 mg / L).

[0088] [Table 4]

[0089] These results indicate that acetylcholine-induced contractions were abolished by exposure to lidocaine.

[0090] Example 6 Example 5 was repeated, except this time benzocaine (70 mg / L) was used instead of lidocaine. The results of the experiment are summarized in Table 5.

[0091] [Table 5]

[0092] Example 7 Example 5 was repeated, except this time bupivacaine (70 mg / L) was used instead of lidocaine. The results of the experiment are summarized in Table 6.

[0093] [Table 6]

[0094] Example 8 Example 5 was repeated, except this time oxethazaine (70 mg / L) was used instead of lidocaine. The results of the experiment are summarized in Table 7.

[0095] [Table 7]

[0096] Example 9 Example 5 was repeated, except this time prilocaine (70 mg / L) was used instead of lidocaine. The results of the experiment are summarized in Table 8.

[0097] [Table 8]

[0098] Example 10 The acid sensitivity of lidocaine was determined by exposing it to acetic acid (pH 2.5) for 1, 5 and 15 minutes and then performing the experiment on fundus strips as in Example 5.

[0099] The results of the experiments are summarized in Table 9.

[0100] [Table 9]

[0101] The results show that lidocaine is inactivated at low pH: only at the shortest exposure time (1 min) does lidocaine remain active and inhibit acetylcholine-induced contractions.

[0102] Example 11 Oral dosage units according to the present invention were prepared according to the formulations shown in Table 10.

[0103] [Table 10]

[0104] These tablets were prepared as follows: lidocaine was sieved on a 600 μm sieve in a tumbling mixer. The other ingredients, except magnesium stearate, were sieved on a 800 μm sieve in a tumbling mixer. The above ingredients were mixed in a tumbling mixer for 15 minutes. Then, magnesium stearate was sieved on a 500 μm sieve and added to the powder mixture, which was then mixed in a tumbling mixer for another 15 minutes. The mixture so obtained was compressed into 10 mm biconvex tablets with an average weight of 318 mg.

[0105] Tablet strength, floating time and disintegration time of the oral dosage units were determined as in Example 2. The results are summarized in Table 11.

[0106] [Table 11]

Claims

1. 1. A gastroretentive oral dosage unit having a weight of 150-1,000 mg, said dosage unit comprising 70-100% by weight of a core unit and 0-30% by weight of a coating, said core unit comprising: (a) 15-50% by weight of a local anesthetic; (b) 2 to 20 wt. % of a blowing agent; (c) 8 to 30 weight percent of a hydrophilic polymer; (d) 5 to 75% by weight of an excipient 16. A gastroretentive oral dosage unit comprising:

2. 2. The dosage unit of claim 1, wherein components (a) through (d) are homogeneously mixed.

3. 3. The dosage unit according to claim 1 or 2, wherein the dosage unit contains 30 to 400 mg of local anesthetic.

4. 4. The dosage unit of any one of claims 1 to 3, wherein the local anesthetic is selected from lidocaine, benzocaine, bupivacaine, oxethazaine, prilocaine, butanilicaine, carticaine, cinchocaine, clibucaine, etidocaine, mepivacaine, ropivacaine, tricaine, trimecaine, vadocaine, articaine, levobupivacaine, amylocaine, cocaine, propanocaine, chlormecaine, cyclomethycaine, proxymethacaine, amethocaine, butacaine, butoxycaine, butyl aminobenzoate, chloroprocaine, dimethocaine, oxybuprocaine, piperocaine, parethoxycaine, procaine, propoxycaine, tricaine, and combinations thereof.

5. 5. The dosage unit of claim 4, wherein the local anesthetic is selected from lidocaine, benzocaine, bupivacaine, oxethazaine, prilocaine, and combinations thereof.

6. 6. The dosage unit of claim 5, wherein the local anesthetic is lidocaine.

7. The dosage unit of any one of claims 1 to 6, wherein the effervescent agent is selected from bicarbonates, carbonates, and combinations thereof.

8. 8. The dosage unit of any one of claims 1 to 7, wherein the hydrophilic polymer is selected from hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, ethyl cellulose, methyl cellulose, carboxymethyl cellulose, carboxymethyl starch, polyethylene oxide, carbomer, polyvinyl alcohol, polyvinylpyrrolidone, vinylpyrrolidone-vinyl acetate copolymer, methacrylic acid copolymer, polyacrylic acid, carrageenan, natural gum, guar gum, tragacanth, acacia gum, locust bean gum, xanthan gum, and combinations thereof.

9. 9. The dosage unit of claim 8, wherein the hydrophilic polymer is hydroxypropyl methylcellulose.

10. The dosage unit of any one of claims 1 to 9, wherein the excipient comprises a filler selected from lactose, microcrystalline cellulose, mannitol, starch and combinations thereof.

11. 11. The dosage unit of claim 10, wherein the core unit contains 20 to 70% by weight of filler.

12. The dosage unit according to any one of claims 1 to 11, wherein the core unit contains a disintegrant selected from croscarmellose, sodium starch glycolate, crospovidone and combinations thereof.

13. The dosage unit of claim 12, wherein the core unit contains 0.5 to 15% by weight of disintegrant.

14. 14. The dosage unit of any one of claims 1 to 13, wherein said combination of components (a) to (d) comprises at least 75% by weight of said core unit.

15. A dosage unit according to any one of claims 1 to 14, wherein the dosage unit comprises 3 to 30% by weight of a saliva-resistant coating.

16. 16. The dosage unit of claim 15, wherein the saliva-resistant coating comprises at least 50% by weight of a cationic copolymer based on dimethylaminoethyl methacrylate.

17. 17. A dosage unit for use in the treatment or prevention of malnutrition or the treatment or prevention of early or excessive satiety in a subject with sufficient nutritional availability, said use comprising oral administration of a dosage unit according to any one of claims 1 to 16.

18. A method for preparing a dosage unit according to any one of claims 1 to 16, comprising the steps of: preparing a tableting mixture by homogeneously mixing components (a), (b), (c) and (d); and compressing the tableting mixture into tablets; The method includes:

Citation Information

Patent Citations

  • gastric retention controlled drug delivery system

    JP2004538301A

  • Pharmaceutical composition for treating gastroesophageal reflux

    US5254591A

  • Means to facilitate food intake and food retention

    WO2013171252A1